[New antibiotics prior to approval: is this the end of the innovative stagnation?].
BACKGROUND
Therapeutic efficacy and safety in infections due to multiresistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase of multiresistant gram-negative and gram-positive organisms, new antibiotics are urgently needed. This paper provides a review of new pharmaceuticals which are already in clinical development, mainly in phase III trials.


CONCLUSIONS
Each of these new trials increases the possibility of new antibiotics receiving approval.
Sektion Klinische Infektiologie, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Pettenkoferstr. 8a, 80336, München, Deutschland, jbogner@med.lmu.de.
J R
JR
Bogner
D000900:Anti-Bacterial Agents / Q000145:classification* / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic / Q000639:trends*; D017277:Drug Approval; D015195:Drug Design; D006801:Humans
D000900:Anti-Bacterial Agents